9. Who am I?
9
My goal: “Improving the utility of clinical trial data. Making it easier
to use data and to be able to take informed decisions when
combining data across clinical trials.”
Industry expert in semantic interoperability, clinical data standards
and medical terminologies.
My first semantic web article from 2000: “Extensible use of RDF in
a business context”.
1.900+ followers on social media (@kerfors) including FDA’s Chief
Health Informatics Officer, AstraZeneca’s CIO and HL7’s CTO.
Contributor to PhUSE, CDISC, W3C HCLS, IMI EHR4CR, MedDRA
MSSO and Advisory Board member for SALUS (Post Market Safety
Studies) EU project.
Informatics Analyst and Lifetime learner
12. Competitive Intelligence 360 (CI360) Approach
Flexibly Addressing Key Questions
Capture Business
Questions and
Sources
Domain Expert
Concept Map
Build Formal
Ontology
Challenge with
Linked Data
Examine with a
Faceted Browser
Share insights
with a Knowledge
Base
14. Translate Questions into Concepts
14
Domain Expert
Concept Map
“Where are the key clinical studies in NSCLC and who are the principle investigators?”
15. Challenge with Data
“Where are the key clinical studies in NSCLC and who are the principle investigators?”
(one example)
Source: https://clinicaltrials.gov/ct2/show/NCT02027428
Challenge with
Linked Data
16. Refine the Answer Examine with a
Faceted Browser
“What are the open trials in metastatic breast cancer and what drugs are being tested?”
17. Share Insights as a Community
“Can a biomarker defined population be added to a trial record?”
Share insights with
a Knowledge Base
18. 2. Our Public, pre-competitive engagement, examples:
Open PHACTS, CDISC/PhUSE, MedDRA and WHO ATC
21. 21
CDISC and PhUSE Semantic Technology
• CDISC2RDF, Oct 2012 a pre-competitive project with AZ,
Roche, W3C et al. to show case Semantic Web
standards and Linked Data principles.
• FDA meeting Nov 2012: Solutions for Study Data
Exchange Standards Meeting – W3C presentation.
• June 2013 the Semantic Technology project, a
FDA/PhUSE working group for Emerging Technologies,
with 25+ repr. from FDA, CDISC, Pharma:s, CRO:s and
software vendors.
• Oct 2013 press release: Representing existing standards
(SDTM, CDASH,SEND, ADaM) in RDF.
• Dec 2014, Public review of CDISC in RDF Guide.
• July 2015, Published on http://www.cdisc.org/rdf and
https://github.com/phuse-org/rdf.cdisc.org
CDISC Interchange Europe
2011 and 2012
presentations from
Roche and AstraZeneca
22.
23.
24. 3. Our Linked Data Community of Practice (LD CoP)
24
6-7 seminars per year
SharePoint site and
Chatter group
Mailing list with 50+
colleagues across IT and
business
Friends and thought leaders
in semantic web and linked data
27. 4. Ongoing work
Identifying Studies via URI:s and programmatic access/APIs
27
Global, persistent, resolvable identifier (AZT_ID) as URI:s
http://clinicaltrials.rd.astrazeneca.net/study/D5896C00725
PREFIX azt: < http://clinicaltrials.rd.astrazeneca.net/study/>
azt:D5896C00725
MLCS
MS_STUDY_ID
IMPACT
TRIAL_NO
CT.GOV
NCT_NUMBER
Data integration/virtualisation
Look up/Master table
connecting AZT_ID:s to database record identifier:s
Resolved via a Look-up Study API
http://clinicaltrials.rd.astrazeneca.net/api/v1/study?azt_id=D5896C00725
Alt. search of the same study e.g.
http://clinicaltrials.rd.astrazeneca.net/api/v1/study?studyname=SD-039-0725
http://clinicaltrials.rd.astrazeneca.net/api/v1/study?studyname=SPROUT
http://clinicaltrials.rd.astrazeneca.net/api/v1/study?studyname=NCT00646321
Surface data
about a study
across databases
URI:s = Uniform Resource Identifier:s
Key to link data about resources/entities in a robust way
Checkout Linked Data Principles
29. AZ/MedImmune
Linked Data Community
Tom Plasterer
Ola Engqvist
Rajan Desai
Jeff Saltzman
David Ruau
Kathy Reinold
Johan Almström
29
Thanks
Key Influencers
David Wood
Lee Harland
Bryn Williams-Jones
Eric Neumann
Dean Allemang
Barend Mons
Carole Goble
Bernadette Hyland
Bob Stanley
Michel Dumontier
John Wilbanks
31. Confidentiality Notice
This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove
it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the
contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus,
Cambridge, CB2 0AA, UK, T: +44(0)203 749 5000, www.astrazeneca.com
31